Directors' Interest in Shares





RNS Number : 4887P
Oxford Biomedica PLC
25 March 2009
 



For Immediate Release

25 March 2009

Oxford BioMedica plc ("the Company")

Directors' Interest in Shares and Share Options

Oxford BioMedica (OXB:L): the Company today announced that on 25 March 2009 the following awards under the Oxford BioMedica plc Long Term Incentive Plan (LTIP) were made to six directors

LTIP: number of shares awarded

Total shares over which options are held (note 1)

Percentage of issued shares under option

John Dawson

2,500,000

5,000,000

0.93%

Alan Kingsman

899,000

3,979,404 2

0.74%

Stuart Naylor

811,000

1,556,494

0.29%

Peter Nolan

854,000

2,466,355

0.46%

Andrew Wood

1,082,000

3,491,974 3

0.65%

Nick Woolf

873,000

3,307,867

0.61%

Notes:

1.    The total shares over which options are held (share options granted to directors up to September 2006 
       and LTIPs
 awarded since March 2007including the awards described above.

2.    Includes 475,000 options held by Susan Kingsman, wife of Alan Kingsman who is a former director

3.    Includes 370,062 options held by Sharon Wood, wife of Andrew Wood, who is a group employee.

The share price on which the LTIP awards were calculated was 6.10p (the closing price on the day preceding the awards). The awards are nil-cost options. The LTIP awards are subject to a three year holding period, and are exercisable on the third anniversary of the award, subject to the satisfaction of a Total Shareholder Return (TSR) performance condition.

No awards will be released at the testing date for less than median performance of Oxford BioMedica TSR compared to a comparator group made up of 20 companies from the biotechnology and healthcare sectors. Median performance will result in release of 25% of the shares. Upper quartile performance (i.e. greater than 75th percentile performance) will result in release of 100% of the shares, with straight line release between these points. If the performance conditions are not satisfied or partially satisfied at the end of the holding period, the LTIP award or the balance of the award (as appropriate) not released shall lapse. There will be no re-testing of the performance conditions.   

In addition, as part of a wider grant of share options to staff, 25,000 share options were granted on 25 March 2009 to Sharon Wood. These options are included in the table above, have an exercise price of 6.10p per share and are exercisable between 3 years and 10 years from the date of grant.

Andrew Wood

Company Secretary, Oxford BioMedica plc

25 March 2009

- Ends -

For further information, please contact:

Oxford BioMedica plc: 

John Dawson, Chief Executive Officer

Tel: +44 (0)1865 783 000

JPMorgan Cazenove Limited:

James Mitford/ Gina Gibson

Tel: +44 (0)20 7588 2828

City/Financial Enquiries:

Lisa Baderoon/ Mark Court/ Mary-Jane Johnson Buchanan Communications

Tel: +44 (0)20 7466 5000

Scientific/Trade Press Enquiries:

Sue Charles/ Holly Griffiths/ John McIntyre

College Hill Life Sciences

Tel: +44 (0)20 7457 2020

US Enquiries:

Thomas Fechtner

The Trout Group LLC

Tel: (646) 378 2900


This information is provided by RNS
The company news service from the London Stock Exchange
 

END

 
 

MSCEAKDSADSNEFE